Otsuka Launches New Molecule In Gastroenterology Segment For Gastritis And Gastric Ulcers

KARACHI - Otsuka hosted a celebratory ceremony at their head office, on launching a new molecule in their Gastroenterology segment for gastric ulcers.

Speaking at the occasion, CEO Otsuka, Mr. Hanif Sattar stated that their company has been bringing the most advanced and research based products to fulfill the need of the medical community. Referring to the most recent advancement, he discussed that, Mucosta (Rebamipide) is a first anti-gastritis and anti-gastric ulcer agent in Pakistan. It is Otsuka’s own research based product, which is producing tremendous results in Japan.

Director Otsuka, Mr. Yahya Feroz added to the conversation that medical companies should work towards benefitting humanity with dignity and continue working skillfully. He acknowledged and wished for Mucosta’s success in Pakistan.

 Chairman Hospital Supply Corporation (HSC), Mr. Mehtabuddin Feroz said that, HSC will continue to serve Otsuka and will support to market Mucosta. Director Distribution Hospital Supply Corporation (HSC), Mr. Hamid Yahya Feroz added that, HSC will provide smart distribution services to bring Mucosta to number one in Pakistan’s market.

Director Marketing, Mr. Tariq Shahid described the market position in gastroenterology segment. He said that his team can get the market share to use with ethical practice; and that Mucosta would be number one in year 2019. Marketing Manager, Mr. Muhammad Arshad Khan added that the team is ready to accept this challenge and bring Mucosta to gastroenterology’s segment in Pakistan.

Ms. Arooj Aslam, the Assistant Product Manager described the product’s mechanism of action and pharmacokinetics, the drug’s effects and side effects.